Kantonsspital St.Gallen
login

Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry

Andreas D Hartkopf, Jens Huober, Bernhard Volz, Naiba Nabieva, Florin-Andrei Taran, Judith Schwitulla, Friedrich Overkamp, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Michael P Lux, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W Beckmann, Erik Belleville, Pauline Wimberger, Carsten Hielscher, Matthias Geberth, Nikos Fersis, Wolfgang Abenhardt, Christian Kurbacher, Rachel Wuerstlein, Christoph Thomssen, Michael Untch, Peter A Fasching, Wolfgang Janni, Tanja N Fehm, Diethelm Wallwiener, Sara Y Brucker & Andreas Schneeweiss

abstract

PURPOSE
This study describes comprehensive data from a breast cancer registry concerning the use of endocrine treatment (ET) and chemotherapy in the first, second and higher therapy lines in hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC).

METHODS
The PRAEGNANT study is a real-time registry for patients with MBC. Therapies were categorized into the following categories: chemotherapy, aromatase inhibitor (AI), tamoxifen, fulvestrant, or everolimus plus ET and reported for first, second and third line or higher therapy use. Also treatment sequences for the first, second and third therapy line were analyzed.

RESULTS
This analysis includes 958 patients with HR positive, HER2 negative MBC. 42.7% were treated with a chemotherapy in the first therapy line compared to 45.9% receiving an ET. A total of 25.9% were treated with everolimus plus anti-hormone therapy in any therapy line. 34.1% were treated with fulvestrant as single agent therapy. Analyzing therapy sequences, the administration of three different chemotherapies in a row was the most frequently used pattern.

CONCLUSIONS
This analysis shows that across all three first therapy lines chemotherapy is a dominant therapy for HR positive, HER2 negative MBC patients. Education about the efficacy of ET might help to increase its use and decrease the possible burden of chemotherapy related toxicities.
   
citation Hartkopf A D, Huober J, Volz B, Nabieva N, Taran F A, Schwitulla J, Overkamp F, Kolberg H C, Hadji P, Tesch H, Häberle L, Ettl J, Lux M P, Lüftner D, Wallwiener M, Müller V, Beckmann M W, Belleville E, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P A, Janni W, Fehm T N, Wallwiener D, Brucker S Y, Schneeweiss A. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. Breast 2017; 37:42-51.
   
type journal paper/review (English)
date of publishing 26-10-2017
journal title Breast (37)
ISSN electronic 1532-3080
pages 42-51
PubMed 29100043
DOI 10.1016/j.breast.2017.10.002